The U.S. Food and Drug Administration (FDA) has granted approval for KEYTRUDA QLEX™, marking a significant advancement in the treatment options available for patients with various solid tumors. This innovative therapy, developed by Merck, known globally as MSD, is the first immune checkpoint inhibitor that can be administered subcutaneously by healthcare providers, allowing for delivery in as little as one minute.
KEYTRUDA QLEX combines pembrolizumab with berahyaluronidase alfa, a variant of human hyaluronidase produced by Alteogen Inc. The new form of administration offers additional convenience over traditional intravenous (IV) administration, significantly reducing the time required for treatment. With two distinct dosing schedules—one-minute injections every three weeks or two-minute injections every six weeks—KEYTRUDA QLEX provides flexibility that can enhance patient experience and streamline treatment processes.
Dr. J. Thaddeus Beck, an oncologist and Medical Director at the Highlands’ Clinical Trials Office, commented on the approval, highlighting its significance for both patients and healthcare providers. The subcutaneous form not only speeds up administration but also increases options for treatment settings, potentially allowing patients to receive therapy in more accessible locations, including doctors’ offices and community clinics.
The pivotal trial which led to the approval compared the subcutaneous formulation of KEYTRUDA QLEX with the traditional IV version in patients with treatment-naïve metastatic non-small cell lung cancer (NSCLC). Results indicated comparable pharmacokinetic exposure levels and similar efficacy, with overall response rates being closely matched between the two forms. Both treatments displayed no notable differences in progression-free survival or overall survival metrics, showing that the new injectable formulation maintains the therapeutic effects of its predecessor.
However, patients and physicians are advised to be aware of potential adverse reactions associated with KEYTRUDA QLEX. Immune-mediated adverse reactions, which can be severe or even fatal, may arise in multiple organ systems. Common serious reactions include pneumonitis, colitis, and endocrinopathies. Early identification and management of these reactions are paramount to ensuring patient safety. Healthcare professionals are encouraged to monitor their patients closely and take appropriate action if severe adverse events occur.
Notably, KEYTRUDA QLEX is not suitable for patients who are hypersensitive to berahyaluronidase alfa or any of its components. Additionally, the therapy poses risks for pregnant women, as it can cause fetal harm, necessitating counseling on contraceptive measures and pregnancy status prior to treatment initiation.
As Merck prepares to release KEYTRUDA QLEX in the U.S. later this month, the company remains committed to improving patient care by providing accessible, effective treatment options. Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck Research Laboratories, emphasized the importance of adapting cancer treatments to align with patient needs, reflecting a growing trend in personalized healthcare solutions.
The approval comes with several indications covering a wide range of cancers, including melanoma, non-small cell lung cancer, head and neck cancers, and more, ensuring that a diverse patient population can benefit from this new offering.
With additional trials and safety data supporting its use, KEYTRUDA QLEX represents a crucial step forward for patients undergoing cancer treatment, embodying Merck’s ongoing dedication to employing scientific innovation in the fight against cancer.
